Quantum量子訊息有限公司
← 最新全球產業報告

Anal Cancer Market

研究執行與發布:Coherent Market Insights · 發布日期 2026-07-01 · 257 頁
由量子訊息有限公司(Quantum Information)在台灣代理銷售與提供授權諮詢。

2026 年市場規模
USD 1,099.9 Mn
2033 年預估規模
USD 1,686.9 Mn
年複合成長率 CAGR
6.3%

以上數字由 Coherent Market Insights 於本報告中提出,量子訊息原樣引用。

出版商 Coherent Market Insights產業別 Healthcare & Life Sciences出版日期 2026-07-01頁數 257報告編號 CMI4701

授權報價

Single User Price$4,500 USD
Enterprise License$10,000 USD
洽詢購買 申請 Sample
完整報告名稱與涵蓋範圍
Anal Cancer Market, By Drug Type(Fluorouracil, Cisplatin, Carboplatin, Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)), By Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, Basal Cell Carcinoma), By Treatment Type (Chemotherapy, Surgery, Radiation Therapy, Immunotherapy), By Distribution Channel (Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Anal cancer is a rare type of cancer in the anal canal. The anal canal is a short tube, about 1-1½ inches long between anal opening and rectum through which stool passes out of the human body. Some of the symptoms associated with anal cancer include anal or rectum bleeding, lump near anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. Anal cancer can be caused due to a number of risk factors such as human papillomavirus (HPV) infection, having multiple sexual partners, indulging in receptive anal intercourse (anal sex), excessive smoking, medical history of vaginal, cervical or vulvar cancers. Moreover, immune-compromised patients who have a disease or condition which causes weakening of immune system such as organ transplant, human immunodeficiency virus (HIV), and others. Market Dynamics The increasing incidence of anal cancer and sexually transmitted diseases, rising research and development activities for the development of novel therapeutics for the treatment of anal cancer, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global anal cancer market over the forecast period. For instance, according to data provided by the Cancer Research U.K. in 2018, around 1,500 new cases of anal cancer are reported every year in the U.K, i.e. four new anal cancer cases daily. The same source also states that the incidence rate of anal cancer in the U.K. is highest in elderly people of age 90 and above. Key features of the study • This report provides in-depth analysis of the global anal cancer market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global anal cancer market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans • Key companies covered as a part of this study include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global anal cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anal cancer market Market Segmentation • By Drug Type Insights (Revenue, USD Mn, 2021 - 2033) o Fluorouracil o Cisplatin o Carboplatin o Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.) • By Cancer Type Insights (Revenue, USD Mn, 2021 - 2033) o Carcinoma In-situ o Squamous Cell Carcinoma o Melanoma o Adenocarcinoma o Basal Cell Carcinoma • By Treatment Type Insights (Revenue, USD Mn, 2021 - 2033) o Chemotherapy o Surgery o Radiation Therapy o Immunotherapy • By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033) o Hospitals & Clinics o Research & Academic Institutes o Long-term Care Centers o Pharmacies • By Region Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  North Africa  Central Africa  South Africa • Key Players o Advaxis, Inc. o ORYX GmbH and Co. KG o Eli Lilly and Company o Merck KGaA o Hoffmann-La Roche Ltd. o GlaxoSmithKline plc o Onconova Therapeutics o BioMimetix JV, LLC o Bayer AG o Spectrum Pharmaceuticals Inc. o Global BioPharma Inc. o Amgen Inc. o Atara Biotherapeutics Inc. o ISA Pharmaceuticals o Takeda Pharmaceutical Company Limited o Ono Pharmaceutical Co., Ltd. o Sun Pharmaceutical Industries Ltd. o Bristol-Myers Squibb Company o Novartis AG o Pfizer Inc. o Sanofi o Johnson & Johnson Private Limited
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Drug Type  Market Snippet, By Cancer Type  Market Snippet, By Treatment Type  Market Snippet, By Distribution Channel  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Pipeline Analysis o PEST Analysis o Regulatory Scenario o Market Trends o Key Highlights o Reimbursement Scenario o Mergers & Acquisitions 4. Global Anal Cancer Market, By Drug Type, 2021 – 2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Fluorouracil  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Cisplatin  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Carboplatin  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) 5. Global Anal Cancer Market, By Cancer Type, 2021 – 2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Carcinoma In-situ  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Squamous Cell Carcinoma  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Melanoma  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Adenocarcinoma  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Basal Cell Carcinoma  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) 6. Global Anal Cancer Market, By Treatment Type, 2021 – 2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Chemotherapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Surgery  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Radiation Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Immunotherapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) 7. Global Anal Cancer Market, By Distribution Channel, 2021 – 2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Hospitals & Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Research & Academic Institutes  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Long-term Care Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) o Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn) 8. Global Anal Cancer Market, By Region, 2021 – 2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2022–2033 o North America  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Cancer Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Treatment Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Country, 2021 – 2033, (USD Mn) o U.S. o Canada o Latin America  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Cancer Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Treatment Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Country, 2021 – 2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Cancer Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Treatment Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Country, 2021 – 2033, (USD Mn) o Germany o U.K. o France o Italy o Spain o Russia o Rest of Europe o Asia Pacific  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Cancer Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Treatment Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Country, 2021 – 2033, (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Cancer Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Treatment Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Country, 2021 – 2033, (USD Mn) o GCC o Israel o Rest of Middle East o Africa  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Cancer Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Treatment Type, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Mn)  Market Size and Forecast, By Region/Country, 2021 – 2033, (USD Mn) o South Africa o Central Africa o North Africa 9. Competitive Landscape o Heat Map Analysis o Market Share Analysis  Advaxis, Inc. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  ORYX GmbH and Co. KG o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Eli Lilly and Company o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Merck KGaA o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  F. Hoffmann-La Roche Ltd. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  GlaxoSmithKline plc o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Onconova Therapeutics o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  BioMimetix JV, LLC o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Bayer AG o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Spectrum Pharmaceuticals Inc. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Global BioPharma Inc. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Amgen Inc. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Atara Biotherapeutics Inc. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  ISA Pharmaceuticals o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Takeda Pharmaceutical Company Limited o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Ono Pharmaceutical Co., Ltd. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Sun Pharmaceutical Industries Ltd. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Bristol-Myers Squibb Company o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Novartis AG o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Pfizer Inc. o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Sanofi o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies  Johnson & Johnson Private Limited o Company Overview o Product Portfolio o Financial Overview o Key Highlights o Market Strategies o Analyst Views 10. Section o References o Research Methodology o About us and Sales Contact

提及公司

Advaxis, Inc.ORYX GmbH and Co. KGEli Lilly and CompanyMerck KGaAHoffmann-La Roche Ltd.GlaxoSmithKline plcOnconova TherapeuticsBioMimetix JV, LLCBayer AGSpectrum Pharmaceuticals Inc.Global BioPharma Inc.Amgen Inc.Atara Biotherapeutics Inc.ISA PharmaceuticalsTakeda Pharmaceutical Company LimitedOno Pharmaceutical Co., Ltd.Sun Pharmaceutical Industries Ltd.Bristol-Myers Squibb CompanyNovartis AGPfizer Inc.SanofiJohnson & Johnson Private Limited

同分類最新報告(醫療與生命科學)

常見問題

這份報告可以先索取樣本嗎?

可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算?

報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付?如何付款?

一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們